

UTILITY PATENT APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: R-247.00CIP

Page 1 of 2

Title: Composition Exhibiting a von Willebrand Factor (vWF)
Protease Activity Comprising a Polypeptide Chain with the Amino
Acid Sequence AAGGILHLELLV

Express Mail Label No.: EL524824544US

APPLICATION ELEMENTS

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

INVENTORS: Bernhard Laemmle Friedrich Scheiflinger
Helena Elisabeth Gerritsen Gerhard Antoine
Miha Furlan Randolph Kerschbaumer
Peter Turecek Luigina Tagliavacca
Hans-Peter Schwarz Klaus Zimmermann

1. ☒ Fee Transmittal Form (Submit an original, and a duplicate for fee processing)

2. ☒ Specification [Total Pages

3. ☒ Drawing(s) (35 USC §113) [Total Pages (Fig. 1-2)

4. ☐ Signed Declaration [Total Pages

a. ☐ Newly executed (original or copy)

b. ☐ Copy from a prior application (37 CFR §1.63(d))

(Note Box 5 below)

i. ☐ DELETION OF INVENTOR(S)

Signed statement attached deleting inventor named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)

5. ☐ Incorporation By Reference (useable if Box 4b is checked.) entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein

6. ☐ Nucleotide and/or Amino Acid Sequence Submission

a. ☐ Computer Readable Copy
b. ☐ Paper Copy (identical to computer copy)
c. ☐ Statement Verifying identity of above copies

7. ☐ Assignment Papers (cover sheet & document(s))

8. ☐ 37 CFR §3.73(b) Statement ☐ Power of Attorney

9. ☐ English Translation Document

16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

10. ☐ Information Disclosure Statement (IDS)/PTO-1449

☐ Copies of IDS Citations

11. ☐ Preliminary Amendment

12. ☒ Return Receipt Postcard (MPEP 503)

13. ☐ Small Entity Statement(s)

14. ☐ Certified Copy of Priority Documents (s)

15a. ☐ Cancel in the application original claims before calculating the filing fee

15b. ☐ Amend the specification by inserting before the first line the sentence: --This is a Continuation, Divisional, Continuation-in-part, of application filed

15c. ☐ I hereby verify that the attached papers are a true copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was Signed. I hereby verify that the papers are a true copy of the latest Signed prior application number filed And further that all statements made herein of my own knowledge Are true; and further that these statements were made with the Knowledge that willful false statements and the like so made are Punishable by fine or imprisonment, or both, under Section 1001 Of Title 18 of the United States Code and that such willful false Statements may jeopardize the validity of the application or any

Patent issuing thereon

15d. ☐ Other

15e. ☐ Other

JC929 U.S. PTO
09/833328
04/12/01

UTILITY PATENT
APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: R-247.00CIP

Page 2 of 2

Title: Composition Exhibiting a von Willebrand Factor (vWF)
Protease Activity Comprising a Polypeptide Chain with the Amino
Acid Sequence AAGGILHLELLV


Express Mail Label No.: EL524824544US

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	35-20 =	15	X \$ <u>18</u> =	\$270
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	7-3 =	4	X \$ <u>80</u> =	\$240
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ <u>270</u> =	\$ 0
				BASIC FEE (37 CFR §1.16(a))	\$710
				TOTAL =	\$1220

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to Deposit Account No. 02 -1437 (Docket R-247.00CIP). (For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. ☒ Fees required under 37 CFR §1.16
- b. ☒ Fees required under 37 CFR §1.17
- c. ☒ Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	Janice Guthrie, Reg. No. 35,170
SIGNATURE	
DATE	April 12, 2001

CORRESPONDENCE ADDRESS

Baxter Healthcare Corporation
P.O. Box 15210
Irvine, California 92614
Telephone: (949) 250-6828 Fax: (949) 474-6330

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10

I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail, Label No. EL524824544US in an envelope addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 on April 12, 2001.

By: 
Diane Branham